From July 1 psychiatrists in Australia will be able to prescribe MDMA and psilocybin for controlled clinical use. Australia’s medicines regulator, the Therapeutic Goods Administration, announced the change in February.
MDMA – 3,4-methylenedioxy-methamphetamine, commonly known as ecstasy – will be used for the treatment of post-traumatic stress disorder. Psilocybin, a psychedelic that forms the active compound in magic mushrooms, will be able to be prescribed for treatment-resistant depression.